Flisiak Robert, Pawłowska Małgorzata, Rogalska-Płońska Magdalena, Bociąga-Jasik Monika, Kłos Krzysztof, Piekarska Anna, Zarębska-Michaluk Dorota
Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540 Bałystok, Poland.
Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 85-067 Bydgoszcz, Poland.
Vaccines (Basel). 2021 Nov 15;9(11):1325. doi: 10.3390/vaccines9111325.
The current study aimed to determine to what extent prior COVID-19 infection affects the response of specific antibodies following vaccination. The study involved 173 healthcare professionals who completed the two-dose vaccination course with BNT162b2, including 40 who previously experienced clinical COVID-19. The levels of anti-SARS-CoV-2 S1S2 IgG (anti-S) and, in some cases, anti-SARS-CoV-S-RBD IgG (anti-S-RBD) were determined six months after complete vaccination. A level exceeding the cut-off values for both anti-S and anti-S-RBD was observed in 100% of subjects, but after setting the analysis to 5- and 10-fold cut-off levels, the percentage of subjects meeting this criterion was significantly higher for anti-S-RBD. The 100-fold cut-off level was achieved by only 21% and 16% for anti-S and anti-S-RBD, respectively. Anti-S and anti-S-RBD levels above ten times the positive cut-off were respectively observed in 91% and 100% individuals with a history of COVID-19, while among those without COVID-19, these values were 64% and 90%, respectively. Significantly higher incidence of values above 10 and 100 times the cut-off became apparent among people with a history of COVID-19. In conclusion, vaccination against COVID-19 following infection with the disease provides higher levels of specific antibodies 6 months after vaccination than those of individuals without a history of the disease, which supports the use of a booster dose, particularly for those who have not experienced SARS-CoV-2 infection.
当前研究旨在确定既往新冠病毒感染在多大程度上影响接种疫苗后特异性抗体的反应。该研究纳入了173名完成BNT162b2两剂疫苗接种疗程的医护人员，其中40人曾经历过临床确诊的新冠病毒感染。在完成疫苗接种6个月后测定抗SARS-CoV-2 S1S2 IgG（抗S）水平，部分情况下还测定了抗SARS-CoV-S-RBD IgG（抗S-RBD）水平。100%的受试者抗S和抗S-RBD水平均超过临界值，但将分析设定为5倍和10倍临界水平时，抗S-RBD达到该标准的受试者百分比显著更高。抗S和抗S-RBD分别仅有21%和16%达到100倍临界水平。有新冠病毒感染史的个体中，分别有91%和100%的人抗S和抗S-RBD水平高于阳性临界值的10倍，而在无新冠病毒感染史的个体中，这些值分别为64%和90%。有新冠病毒感染史的人群中，高于临界值10倍和100倍的发生率明显更高。总之，感染新冠病毒后接种疫苗，在接种6个月后产生的特异性抗体水平高于无该疾病史的个体，这支持使用加强针，特别是对于未感染过SARS-CoV-2的人群。
